NO317747B3 - Farmasoytisk preparat samt anvendelse derav - Google Patents
Farmasoytisk preparat samt anvendelse derav Download PDFInfo
- Publication number
- NO317747B3 NO317747B3 NO19983812A NO983812A NO317747B3 NO 317747 B3 NO317747 B3 NO 317747B3 NO 19983812 A NO19983812 A NO 19983812A NO 983812 A NO983812 A NO 983812A NO 317747 B3 NO317747 B3 NO 317747B3
- Authority
- NO
- Norway
- Prior art keywords
- aspirin
- clopidogrel
- active ingredients
- pharmaceutical preparation
- stated
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 39
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims abstract description 34
- 229960003009 clopidogrel Drugs 0.000 claims abstract description 34
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 8
- 206010002388 Angina unstable Diseases 0.000 claims description 6
- 208000007814 Unstable Angina Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 230000009424 thromboembolic effect Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 238000013171 endarterectomy Methods 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010061216 Infarction Diseases 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 230000002600 fibrillogenic effect Effects 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 230000007574 infarction Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- USKPQBRNXDJQGX-CKUXDGONSA-N 2-acetyloxybenzoic acid;methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric acid Chemical compound OS(O)(=O)=O.CC(=O)OC1=CC=CC=C1C(O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl USKPQBRNXDJQGX-CKUXDGONSA-N 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 18
- 229960005001 ticlopidine Drugs 0.000 description 18
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 18
- 208000007536 Thrombosis Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 230000002744 anti-aggregatory effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960002768 dipyridamole Drugs 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004676 antithrombotic agent Drugs 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003966 vascular damage Effects 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102100032392 Circadian-associated transcriptional repressor Human genes 0.000 description 1
- 101710130150 Circadian-associated transcriptional repressor Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010052664 Vascular shunt Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003970 cerebral vascular damage Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9602027A FR2744918B1 (fr) | 1996-02-19 | 1996-02-19 | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| PCT/FR1997/000296 WO1997029753A1 (fr) | 1996-02-19 | 1997-02-17 | Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO983812D0 NO983812D0 (no) | 1998-08-19 |
| NO983812L NO983812L (no) | 1998-10-09 |
| NO317747B1 NO317747B1 (no) | 2004-12-13 |
| NO317747B3 true NO317747B3 (no) | 2011-10-03 |
Family
ID=9489354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983812A NO317747B3 (no) | 1996-02-19 | 1998-08-19 | Farmasoytisk preparat samt anvendelse derav |
| NO2010015C NO2010015I2 (no) | 1996-02-19 | 2010-07-09 | Klopidogrel og acetylsalicylsyre eller famasøytiskaksepterbare salter derav |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2010015C NO2010015I2 (no) | 1996-02-19 | 2010-07-09 | Klopidogrel og acetylsalicylsyre eller famasøytiskaksepterbare salter derav |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5989578A (pt) |
| EP (1) | EP0881901B1 (pt) |
| JP (1) | JP3662028B2 (pt) |
| KR (1) | KR100295345B1 (pt) |
| CN (1) | CN1116042C (pt) |
| AT (1) | ATE218870T1 (pt) |
| AU (1) | AU715655B2 (pt) |
| BR (1) | BR9707556A (pt) |
| CA (1) | CA2246289C (pt) |
| CZ (1) | CZ292363B6 (pt) |
| DE (2) | DE69713287T2 (pt) |
| DK (1) | DK0881901T3 (pt) |
| EE (1) | EE03513B1 (pt) |
| ES (1) | ES2176684T3 (pt) |
| FR (1) | FR2744918B1 (pt) |
| HK (1) | HK1017850A1 (pt) |
| HU (1) | HU225036B1 (pt) |
| IL (1) | IL125848A (pt) |
| IS (1) | IS1892B (pt) |
| NO (2) | NO317747B3 (pt) |
| NZ (1) | NZ331444A (pt) |
| PL (1) | PL187292B1 (pt) |
| PT (1) | PT881901E (pt) |
| RU (1) | RU2184547C2 (pt) |
| SI (1) | SI0881901T1 (pt) |
| SK (1) | SK284285B6 (pt) |
| TR (1) | TR199801608T2 (pt) |
| UA (1) | UA51695C2 (pt) |
| WO (1) | WO1997029753A1 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322824A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| WO1999065500A1 (en) | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| US6509348B1 (en) | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| FR2792836B3 (fr) | 1999-04-30 | 2001-07-27 | Sanofi Sa | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
| FR2797400A1 (fr) * | 1999-08-11 | 2001-02-16 | Sanofi Synthelabo | Associations a activite anti-thrombotique constituees de l'hydrogenosulfate de clopidogrel et d'un antagoniste des recepteurs gpiib/iiia et les compositions pharmaceutiques les contenant |
| PL206138B1 (pl) * | 2000-12-25 | 2010-07-30 | Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited | Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| FR2832929A1 (fr) * | 2001-12-05 | 2003-06-06 | Sanofi Synthelabo | Compositions pharmaceutiques contenant un agent antithrombotique et un derive d'amines cycliques |
| AU2003270861A1 (en) * | 2002-10-02 | 2004-04-23 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| ATE536889T1 (de) | 2003-07-08 | 2011-12-15 | Accumetrics Inc | Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten |
| HUP0400982A2 (en) * | 2004-05-17 | 2006-08-28 | Chemor Kutato | New veterinary product for honeybees |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| EP1926736A4 (en) * | 2005-09-21 | 2010-08-25 | Chong Kun Dang Pharm Corp | NEW RESINATE COMPLEX OF S-CLOPIDOGREL AND METHOD FOR THE PRODUCTION THEREOF |
| WO2008048083A1 (es) * | 2006-10-17 | 2008-04-24 | Espinosa Abdala Leopoldo De Je | Composiciones farmacéuticas para el tratamiento de enfermedades tromboembólicas |
| DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| KR20160033792A (ko) | 2007-04-27 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법 |
| KR100949273B1 (ko) * | 2008-02-22 | 2010-03-25 | 한올제약주식회사 | 복합제제 |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| US8236782B2 (en) * | 2009-05-13 | 2012-08-07 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| EA021588B1 (ru) | 2009-06-25 | 2015-07-30 | Тетра Сиа | Бетаиновые соли ацетилсалициловой кислоты |
| US8563574B2 (en) | 2009-12-07 | 2013-10-22 | Academic Pharmaceuticals, Inc. | Parenteral formulation of clopidogrel |
| CN102389436A (zh) * | 2011-09-09 | 2012-03-28 | 北京阜康仁生物制药科技有限公司 | 一种抗血小板聚集的药物组合物 |
| KR101675501B1 (ko) * | 2011-11-02 | 2016-11-14 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
| US8513278B2 (en) | 2011-11-26 | 2013-08-20 | Academic Pharmaceuticals, Inc. | Parenteral dextrose formulation of clopidogrel |
| CN102406938A (zh) * | 2011-11-29 | 2012-04-11 | 北京阜康仁生物制药科技有限公司 | 一种抗血栓的药物组合物 |
| WO2013133620A1 (en) * | 2012-03-09 | 2013-09-12 | Yuhan Corporation | Pharmaceutical composition comprising clopidogrel and aspirin and process for preparing the same |
| CN103720700A (zh) * | 2012-10-10 | 2014-04-16 | 江苏威凯尔医药科技有限公司 | 含有阿斯匹林和维卡格雷的药用组合物 |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| KR101502588B1 (ko) | 2013-05-01 | 2015-03-16 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
| WO2015015062A1 (fr) * | 2013-08-02 | 2015-02-05 | Sanofi | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
| HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
| CN107698620A (zh) * | 2015-06-23 | 2018-02-16 | 江苏天士力帝益药业有限公司 | 一种氘代噻吩并哌啶衍生物、制备方法及其应用 |
| RU2745774C1 (ru) * | 2020-08-14 | 2021-03-31 | Алексей Викторович Марочков | Способ лечения пациентов с новой коронавирусной инфекцией (covid-19) |
| US20230059869A1 (en) | 2021-08-03 | 2023-02-23 | Liqmeds Worldwide Limited | Oral pharmaceutical solution of clopidogrel |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2307538A1 (fr) * | 1975-04-18 | 1976-11-12 | Centre Etd Ind Pharma | Nouveau medicament anti-agregant plaquettaire |
-
1996
- 1996-02-19 FR FR9602027A patent/FR2744918B1/fr not_active Expired - Fee Related
-
1997
- 1997-02-17 EE EE9800247A patent/EE03513B1/xx not_active IP Right Cessation
- 1997-02-17 HU HU9901144A patent/HU225036B1/hu active Protection Beyond IP Right Term
- 1997-02-17 IL IL12584897A patent/IL125848A/xx not_active IP Right Cessation
- 1997-02-17 WO PCT/FR1997/000296 patent/WO1997029753A1/fr active IP Right Grant
- 1997-02-17 CA CA002246289A patent/CA2246289C/fr not_active Expired - Lifetime
- 1997-02-17 JP JP52906097A patent/JP3662028B2/ja not_active Expired - Lifetime
- 1997-02-17 RU RU98117511/14A patent/RU2184547C2/ru active
- 1997-02-17 SK SK1105-98A patent/SK284285B6/sk not_active IP Right Cessation
- 1997-02-17 PL PL97327923A patent/PL187292B1/pl unknown
- 1997-02-17 NZ NZ331444A patent/NZ331444A/en not_active IP Right Cessation
- 1997-02-17 AT AT97905218T patent/ATE218870T1/de active
- 1997-02-17 SI SI9730355T patent/SI0881901T1/xx unknown
- 1997-02-17 CZ CZ19982499A patent/CZ292363B6/cs not_active IP Right Cessation
- 1997-02-17 UA UA98094800A patent/UA51695C2/uk unknown
- 1997-02-17 DE DE69713287T patent/DE69713287T2/de not_active Expired - Lifetime
- 1997-02-17 CN CN97192393A patent/CN1116042C/zh not_active Expired - Lifetime
- 1997-02-17 DK DK97905218T patent/DK0881901T3/da active
- 1997-02-17 KR KR1019980706556A patent/KR100295345B1/ko not_active IP Right Cessation
- 1997-02-17 AU AU18844/97A patent/AU715655B2/en not_active Revoked
- 1997-02-17 DE DE201012000030 patent/DE122010000030I2/de active Active
- 1997-02-17 EP EP97905218A patent/EP0881901B1/fr not_active Expired - Lifetime
- 1997-02-17 BR BR9707556A patent/BR9707556A/pt not_active IP Right Cessation
- 1997-02-17 PT PT97905218T patent/PT881901E/pt unknown
- 1997-02-17 US US09/117,904 patent/US5989578A/en not_active Expired - Lifetime
- 1997-02-17 TR TR1998/01608T patent/TR199801608T2/xx unknown
- 1997-02-17 ES ES97905218T patent/ES2176684T3/es not_active Expired - Lifetime
-
1998
- 1998-08-18 IS IS4827A patent/IS1892B/is unknown
- 1998-08-19 NO NO19983812A patent/NO317747B3/no not_active IP Right Cessation
-
1999
- 1999-07-08 HK HK99102920A patent/HK1017850A1/xx not_active IP Right Cessation
-
2010
- 2010-07-09 NO NO2010015C patent/NO2010015I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317747B3 (no) | Farmasoytisk preparat samt anvendelse derav | |
| NO323739B1 (no) | Preparater for behandling og forebygging av arteriell trombose og anvendelse av en faktor Xa inhibitor kombinert med et antiblodplateaggregeringsmiddel | |
| Andersson et al. | Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks | |
| NO327973B1 (no) | Anvendelse av en kombinert ostroprogestativ forbindelse for fremstilling av et medikament for korreksjon av ostrogenforstyrrelser hos kvinner samt forebyggelse av osteoporose og kardiovaskulaere sykdommer hos kvinner i overgangsalder | |
| Bousser | Migraine, female hormones, and stroke | |
| CA2100777C (en) | Pharmaceutical composition containing granisetron and dexamethasone | |
| EP1064021B1 (en) | Use of cysteinprotease inhibitors for the manufacture of a medicament for prevention and treatment of brain tissue impairment due to hypertensive encephalopathy or encephalothlipsis. | |
| JPS60139621A (ja) | 抗血栓剤 | |
| US4652581A (en) | Tetrahydroindole derivative as medicament for cerebral apoplexy | |
| KR101962518B1 (ko) | 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물 | |
| JPH0445494B2 (pt) | ||
| Keyser | Platelet aggregation inhibitors in neurology | |
| Elis | Drugs used in tuberculosis and leprosy | |
| JPH03115220A (ja) | 非心臓由来の不整脈防止薬 | |
| JPH0219806B2 (pt) | ||
| JPS61236725A (ja) | 脳浮腫抑制剤 | |
| Woodall | iChronic Bronchitisthrp thatworkswhereitshould. | |
| Shastri et al. | Drugs of Ophthalmic Concern in Pregnancy | |
| ITMI941117A1 (it) | Impiego di cisteamina come prodotto antiretrovirale | |
| Ashford | angina: comparison with the effects of treatment | |
| IE903351A1 (en) | Novel treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: SAMMENSETNINGEN AV KLOPIDOGREL OG ACETYLSALICYLSYRE (ASPIRIN) ER PRODUKTET AV STOFFENE DUOPLAVIN OG DUOCOVER. KLOPIDOGREL OG ACETYLSALICYLSYRE OMFATTES I.A. AV GRUNDPATENTETS KRAV 1. SE OGSA THE MERCK INDEX; NAT. REG. NO/DATE: EU/1/10/619/001/NO 20100323; FIRST REG. NO/DATE: EU/1/10/619/001-014 20100315 Spc suppl protection certif: 2010015 Filing date: 20100709 |
|
| LC4 | Limitation of patent rights - b3 (par. 39b patent act) |
Effective date: 20111003 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: SAMMENSETNINGEN AV KLOPIDOGREL OG ACETYLSALICYLSYRE (ASPIRIN) ER PRODUKTET AV STOFFENE DUOPLAVIN OG DUOCOVER. KLOPIDOGREL OG ACETYLSALICYLSYRE OMFATTES I.A. AV GRUNDPATENTETS KRAV 1. SE OGSA THE MERCK INDEX; NAT. REG. NO/DATE: EU/1/10/619/001/NO 20100323; FIRST REG. NO/DATE: EU/1/10/619/001-014 20100315 Spc suppl protection certif: 2010015 Filing date: 20100709 Extension date: 20220217 |
|
| MK1K | Patent expired |